CRISPR Therapeutics AG’s recent filing unveils that its Chief Executive Officer Kulkarni Samarth unloaded Company’s shares for reported $1.67 million on Nov 11 ’24. In the deal valued at $55.62 per share,30,000 shares were sold. As a result of this transaction, Kulkarni Samarth now holds 196,540 shares worth roughly $9.69 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, KASINGER JAMES R. sold 1,089 shares, generating $50,399 in total proceeds. Upon selling the shares at $46.28, the General Counsel and Secretary now owns 62,597 shares.
Before that, Kulkarni Samarth sold 4,293 shares. CRISPR Therapeutics AG shares valued at $198,680 were divested by the Chief Executive Officer at a price of $46.28 per share. As a result of the transaction, Kulkarni Samarth now holds 226,540 shares, worth roughly $11.17 million.
Needham reiterated its CRISPR Therapeutics AG [CRSP] rating to a Buy in a research note published on August 06, 2024; the price target was $84. A number of analysts have revised their coverage, including Rodman & Renshaw’s analysts, who began to cover the stock in early August with a ‘”a Buy”‘ rating. Wolfe Research started covering the stock on February 15, 2024. It rated CRSP as “a Peer perform”.
Price Performance Review of CRSP
On Tuesday, CRISPR Therapeutics AG [NASDAQ:CRSP] saw its stock fall -2.16% to $49.31. Over the last five days, the stock has gained 4.98%. CRISPR Therapeutics AG shares have fallen nearly -21.23% since the year began. Nevertheless, the stocks have fallen -31.14% over the past one year. While a 52-week high of $91.10 was reached on 02/22/24, a 52-week low of $43.42 was recorded on 09/06/24. SMA at 50 days reached $48.02, while 200 days put it at $56.81.
Levels Of Support And Resistance For CRSP Stock
The 24-hour chart illustrates a support level at 48.32, which if violated will result in even more drops to 47.34. On the upside, there is a resistance level at 50.46. A further resistance level may holdings at 51.62. The Relative Strength Index (RSI) on the 14-day chart is 52.03, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.03, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 71.97%. Stochastics %K at 27.19% indicates the stock is a holding.
How much short interest is there in CRISPR Therapeutics AG?
A steep rise in short interest was recorded in CRISPR Therapeutics AG stocks on 2024-11-15, growing by 1.8 million shares to a total of 19.39 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 17.59 million shares. There was a rise of 9.27%, which implies that there is a positive sentiment for the stock.
